Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Alcohol Clin Exp Res ; 40(3): 553-62, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26857685

RESUMO

BACKGROUND: Several peroxisome proliferator-activated receptor (PPAR) agonists reduce voluntary alcohol consumption in rodent models, and evidence suggests that PPARα and γ subunits play an important role in this effect. To define the subunit dependence of this action, we tested selective PPARα and α/γ agonists and antagonists in addition to null mutant mice lacking PPARα. METHODS: The effects of fenofibrate (PPARα agonist) and tesaglitazar (PPARα/γ agonist) on continuous and intermittent 2-bottle choice drinking tests were examined in male and female wild-type mice and in male mice lacking PPARα. We compared the ability of MK886 (PPARα antagonist) and GW9662 (PPARγ antagonist) to inhibit the effects of fenofibrate and tesaglitazar in wild-type mice. The estrogen receptor antagonist, tamoxifen, can inhibit PPARγ-dependent transcription and was also studied in male and female mice. RESULTS: Fenofibrate and tesaglitazar reduced ethanol (EtOH) consumption and preference in wild-type mice, but these effects were not observed in mice lacking PPARα. MK886 inhibited the action of fenofibrate, but not tesaglitazer, while GW9662 did not inhibit either agonist. The PPAR agonists were more effective in male mice compared to females, and drinking in the continuous 2-bottle choice test was more sensitive to fenofibrate and tesaglitazar compared to drinking in the intermittent access test. Tamoxifen also reduced EtOH consumption in male mice and this action was inhibited by GW9662, but not MK886, suggesting that it acts by activation of PPARγ. CONCLUSIONS: Our study using selective PPAR agonists, antagonists, and null mutant mice indicates a key role for PPARα in mediating reduced EtOH consumption by fenofibrate and tesaglitazar.


Assuntos
Consumo de Bebidas Alcoólicas/tratamento farmacológico , PPAR alfa/agonistas , PPAR alfa/fisiologia , PPAR gama/agonistas , PPAR gama/fisiologia , Subunidades Proteicas/agonistas , Alcanossulfonatos/farmacologia , Alcanossulfonatos/uso terapêutico , Anilidas/farmacologia , Animais , Relação Dose-Resposta a Droga , Etanol/administração & dosagem , Feminino , Fenofibrato/farmacologia , Fenofibrato/uso terapêutico , Indóis/farmacologia , Masculino , Camundongos , Camundongos da Linhagem 129 , Camundongos Knockout , PPAR alfa/antagonistas & inibidores , PPAR gama/antagonistas & inibidores , Fenilpropionatos/farmacologia , Fenilpropionatos/uso terapêutico , Subunidades Proteicas/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA